Julia Rochotte

Inserm — France

Immunology and Microbiology · Life Sciences

5h-index311citations38works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(19), Cancer Immunotherapy and Biomarkers(15), CAR-T cell therapy research(13), Sphingolipid Metabolism and Signaling(9), Pancreatic and Hepatic Oncology Research(8)

Publications38 total

Supplementary Data File S1 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Data from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Supplementary Data File S1 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Supplementary Tables and Figures from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Supplementary Data File S2 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Supplementary Data File S2 from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Data from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Supplementary Tables and Figures from Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti–PD-1 Therapy Efficacy
2023Open Access
Supplementary Figure S6 from Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
2023Open Access
Supplementary information from Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
2023Open Access
Supplementary Figure S4 from Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
2023Open Access
Supplementary Figure S5 from Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
2023Open Access
Supplementary Figure S5 from Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
2023Open Access
Supplementary Figure S2 from Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
2023Open Access
Supplementary Figure S7 from Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
2023Open Access
Supplementary Figure S3 from Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
2023Open Access
Supplementary Figure S1 from Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
2023Open Access
Supplementary Figure S2 from Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
2023Open Access
Data from Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
2023Open Access
Supplementary Figure S6 from Blocking Tumor Necrosis Factor α Enhances CD8 T-cell–Dependent Immunity in Experimental Melanoma
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Florie Bertrand(29), Céline Colacios(29), Anne Montfort(29), Nathalie Andrieu‐Abadie(29), Thierry Levade(29), Hervé Benoist(29), Bruno Ségui(29), Philippe Rochaix(28), Anne‐Françoise Tilkin‐Mariamé(19), Christian Touriol(19), Isabelle Lajoie‐Mazenc(19), Julia Gilhodes(9), Thomas Filleron(9), Jean Milhès(9), Carine Dufau(9), Caroline Imbert(9), Joëlle Riond(9), Marie Tosolini(9), Christopher J. Clarke(9), Florent Dufour(9)